We are excited to announce that our 2019 Congress will feature an interactive half-day workshop for Young Investigators on 5 February on the topics of:
1. Finding the answer to your question – a workshop on study design
2. How to write and publish your research
Research projects have the aim to answer questions that are vital for medical progress. To perform a successful research project, it is essential to formulate the right research question and to use the right design for the study. Once the study is completed, it is paramount to share your results by getting them published.
The aim of this Young Investigator Workshop is to teach clinical and translational researchers:
1. How to formulate the right research question
2. How to choose the correct study design
3. How to write up your research for publication, with tips on how to increase your chances of getting your paper accepted at the first attempt
Participants will be asked to prepare a short presentation on one of their research projects, within the clinical or translational domain. Basic experimental research projects do not qualify.
While it is not mandatory to present a research project, participants who volunteer to do so will receive a certificate attesting to this.
Register for the workshop via the EAHAD 2019 Congress website.
Have a question before registering? Contact us at email@example.comClick here to see the full post
EAHAD is inviting haemophilia nurses to apply for two vacant posts on its Nurses Committee.
To apply to join the Nurses Committee, please send a short letter of motivation (maximum 300 words) outlining why you wish to be a part of the committee. Please also include in the letter the following information:Click here to see the full post
This week, Wiley appointed Prof Cedric Hermans as the new Editor-in-Chief, of Haemophilia, the official journal of EAHAD. Prof Hermans, EAHAD’s Past-President, replaces Prof Michael Makris and Dr Craig Kessler, who step down from their editorial posts this month and at the end of the year, respectively.
Click here to see the full post
For the past three decades, haemophilia A and B patients have been treated using FVIII and FIX replacement concentrates. These therapies are well known to clinicians and patients.
A promising new era has now begun in the treatment of haemophilia and rare bleeding disorders. A series of novel, non-replacement therapies are becoming available, which may significantly impact the clinical care and quality of life of patients. The European Association for Haemophilia and Allied Disorders (EAHAD) and the European Haemophilia Consortium (EHC) welcome all novel therapies that have a meaningful impact on patients' treatment, care and quality of life.Click here to see the full post
On 19 June, EAHAD participated in the Round Table of Stakeholders on “Women and Bleeding Disorders”. Organised by the European Haemophilia Consortium (EHC), the event took place in the European Parliament in Brussels. Members of the European Parliament from different political groups also participated in the event, with Jana Žitňanská, MEP, chairing the Round Table.Click here to see the full post